AtaiBeckley Gets $209.9M Runway, Begins BPL-003 Phase 3, Eyes Q4 VLS-01 Data
AtaiBeckley closed Q1 2026 with $209.9M cash funding operations into 2029, initiated its Phase 3 ReConnection program for BPL-003 in TRD and awaits VLS-01 Phase 2 topline data in Q4. R&D expenses rose to $17.4M as EMP-01 Phase 2a validated its SAD therapeutic potential.
1. Financial Results
AtaiBeckley ended Q1 2026 with $209.9M in cash and equivalents, down from $220.7M at December 31, 2025, providing a runway into early 2029. R&D expenses increased to $17.4M and G&A to $14.4M, driving a net loss of $29.8M as clinical and personnel costs rose.
2. Clinical Pipeline Update
The Phase 3 ReConnection program for BPL-003 in treatment-resistant depression is on track to initiate in Q2 2026, enrolling ~580 patients across two pivotal studies with a 52-week open-label extension. EMP-01’s Phase 2a trial demonstrated consistent clinician-rated and patient-reported improvements in social anxiety disorder.
3. Upcoming Milestones
VLS-01 Elumina Phase 2 topline results are expected in Q4 2026, and BPL-003 Phase 2a Part 4 two-dose induction data is targeted for later this year. The company was added to the S&P Biotechnology Select Industry Index and appointed Michael Faerm as CFO effective March 2026.